Lumos Pharma Inc (LUMO) - Financial and Strategic SWOT Analysis Review

August 2021 | 49 pages | ID: N20BC3ACC6BEN
GlobalData

Abstracts

Lumos Pharma Inc (LUMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lumos Pharma Inc (Lumos Pharma), formerly NewLink Genetics Corp is a clinical stage biopharmaceutical company that focuses on the development and commercialization of new therapies for the treatment of unmet medical needs of rare diseases. The company’s lead investigating candidate, LUM-201 (ibutamoren) is an oral growth hormone stimulating therapy for the treatment of pediatric growth hormone deficiency (PGHD), turner syndrome, children born small for gestational age (SGA), and other rare endocrine disorders. Lumos Pharma is headquartered in Austin, Texas, the US.

Lumos Pharma Inc Key Recent Developments

Aug 05,2021: Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
Aug 03,2021: Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
Aug 02,2021: Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
Jul 26,2021: Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
May 05,2021: Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Lumos Pharma Inc - Key Facts
Lumos Pharma Inc - Key Employees
Lumos Pharma Inc - Key Employee Biographies
Lumos Pharma Inc - Major Products and Services
Lumos Pharma Inc - History
Lumos Pharma Inc - Company Statement
Lumos Pharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Lumos Pharma Inc - Business Description
R&D Overview
Lumos Pharma Inc - Corporate Strategy
Lumos Pharma Inc - SWOT Analysis
SWOT Analysis - Overview
Lumos Pharma Inc - Strengths
Lumos Pharma Inc - Weaknesses
Lumos Pharma Inc - Opportunities
Lumos Pharma Inc - Threats
Lumos Pharma Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Lumos Pharma Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 05, 2021: Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
Aug 03, 2021: Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
Aug 02, 2021: Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
Jul 26, 2021: Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
May 05, 2021: Lumos Pharma Reports First Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
Apr 20, 2021: Lumos Pharma Announces Retirement of Carl Langren and Names Lori Lawley Chief Financial Officer in Planned Succession
Mar 11, 2021: Lumos Pharma to Participate in March 2021 Investor Conferences
Feb 22, 2021: Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
Feb 16, 2021: Lumos Pharma Announces Changes to its Board of Directors
Nov 10, 2020: Lumos Pharma announces the initiation of phase 2b OraGrowtH210 trial and reports third quarter 2020 financial results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Lumos Pharma Inc, Key Facts
Lumos Pharma Inc, Key Employees
Lumos Pharma Inc, Key Employee Biographies
Lumos Pharma Inc, Major Products and Services
Lumos Pharma Inc, History
Lumos Pharma Inc, Other Locations
Lumos Pharma Inc, Subsidiaries
Lumos Pharma Inc, Key Competitors
Lumos Pharma Inc, Ratios based on current share price
Lumos Pharma Inc, Annual Ratios
Lumos Pharma Inc, Annual Ratios (Cont...1)
Lumos Pharma Inc, Interim Ratios
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Lumos Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Lumos Pharma Inc, Performance Chart (2016 - 2020)
Lumos Pharma Inc, Ratio Charts
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Lumos Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021